Ghayas C. Issa
First author of the revumenib trial that created the menin inhibitor class for acute leukaemia.
Overview
Ghayas Issa led and was first author of the AUGMENT-101 phase 1 report in Nature showing the menin inhibitor revumenib produces remissions in heavily pretreated KMT2A-rearranged and NPM1-mutant acute leukaemia, and of the pivotal phase 2 analysis that led to its 2024 approval. He leads menin inhibitor combination trials and studies of resistance (MEN1 mutations) at MD Anderson.
Pages like this
not linked directly; found by shared links- PersonEytan M. Stein
Shares AUGMENT-101, AUGMENT-101: revumenib, the first menin inhibitor, in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation, Revumenib, Menin and the tags aml, menin.
- CompanySyndax Pharmaceuticals
Shares AUGMENT-101: revumenib, the first menin inhibitor, in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation, Revumenib, Acute myeloid leukaemia.
- IdeaMenin inhibitors for infant KMT2A-rearranged ALL
Shares AUGMENT-101, Revumenib, Menin, Acute lymphoblastic leukaemia.
- TargetKMT2A (MLL) rearrangement
Shares AUGMENT-101, AUGMENT-101: revumenib, the first menin inhibitor, in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation, Revumenib, Menin.
- PersonAlexander E. Perl
Shares Acute myeloid leukaemia and the tags aml, targeted-therapy.
- PairingMenin inhibitor + venetoclax + azacitidine
Shares AUGMENT-101: revumenib, the first menin inhibitor, in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation, Revumenib, Menin, Acute myeloid leukaemia.
- PathwayMenin / KMT2A (HOXA9-MEIS1 axis)
Shares Revumenib, Menin, Acute lymphoblastic leukaemia, Acute myeloid leukaemia.
- TargetNPM1 mutation
Shares AUGMENT-101, AUGMENT-101: revumenib, the first menin inhibitor, in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation, Revumenib, Menin.